Neovii Pharmaceuticals AG Establishes Global Scientific Department
Neovii continues to strengthen its leadership team and capabilities with the appointment of Richard Sachse as Global Chief Scientific Officer. With the appointment of Dr. Sachse, Neovii has set up a Global Scientific Department which comprises all regulatory, medical, and development activities globally.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180703005142/en/
Richard Sachse, Global Chief Scientific Officer, Neovii (Photo: Business Wire)
Neovii’s CEO Juergen Pohle commented: “By establishing a Global Scientific Department, Neovii makes another step forward to become a leading biopharmaceutical company in the transplantation segment.” He added: “We are very excited that Richard joins Neovii and will establish the new Global Scientific Department. His deep understanding and long-term experience in clinical development and regulatory activities, as well as his know-how and strong leadership skills, make him the right person to push this role forward and to drive the business into our next chapter.” Dr. Sachse will also join Neovii’s Global Leadership Team.
Dr. Sachse previously held the position of Senior Vice President, Chief Scientific Officer, and Chief Medical Officer at Æterna Zentaris. In this role Dr. Sachse succeeded in designing and completing development programs for FDA drug approval. He draws on more than 20 years of experience in the pharmaceutical industry not only at Æterna Zentaris, but also with Boehringer Ingelheim, UCB, Schwarz Biosciences, Peptor, and Bayer.
Richard Sachse pointed out: “I am excited to join Neovii and to build the new Global Scientific Department comprising regulatory, medical, and development activities. Driving Neovii to become a full-fledged pharmaceutical company is a challenging but rewarding task, and I am certain that my previous experience will highly benefit Neovii. I am enthusiastic to begin working with our in-licensing partners to provide better paths to key markets for the most innovative lines of treatments in transplantation and rare diseases.”
Neovii also appointed former Pfizer executive Alfred Doucette as Global CFO at the beginning of the year. Alfred Doucette has held several senior finance positions within Pfizer and was most recently the Commercial Director for Pfizer Consumer Healthcare for the SEE/CIS/Baltics/Greece & Cyprus, Israel and Turkey regions, bringing a huge wealth of experience in financial management.
About Neovii
Neovii is an independent, dynamic, rapidly-growing and global biopharmaceutical company with a patient-focused mission to develop and market novel life-transforming therapies.
Neovii has been dedicated for over three decades to improving the outcomes in transplantation medicine and the treatment options for hemato-oncological as well as immune disorders.
Neovii Pharmaceuticals AG’s global headquarters is located in Rapperswil, Switzerland and has a branch office in Lexingtion MA, USA. Its biotechnology manufacturing facility is in Graefelfing, Germany. Neovii’s products are available in over 50 countries worldwide.
For further information
For further information, please visit www.neovii.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180703005142/en/
Contact information
For Neovii Pharmaceuticals AG
Daniela Suter, 0041 (0)44 455 84 25
daniela.suter@bm.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
H.I.G. Capital Announces the Sale of DGS S.p.A.11.6.2024 12:00:00 CEST | Press release
H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with $62 billion of capital under management, is pleased to announce that an affiliate has signed a definitive agreement to sell its portfolio company, DGS S.p.A. (“DGS” or the “Group”), a leading firm in the Italian Information Technology market, to DGS Co-Founders and management team in partnership with ICG, a global alternative asset manager. Since its inception in 1997, DGShas supported blue-chip customers in the design, integration, and maintenance of complex IT systems, with a specialization in digital transformation and cybersecurity services. The Group currently has over 1,900 employees, revenues of approximately €300 million, and maintains a group of highly loyal clientele. During H.I.G.’s ownership, DGS has tripled in size and consolidated its position as a leading Italian firm in cybersecurity services and digital transformation. DGS offers its clients sophisticated and proprietary digital transformation
Evertas Names Nick Selby Head of European Underwriting11.6.2024 12:00:00 CEST | Press release
Evertas, the world’s first crypto insurance company, has named Nick Selby as its new Head of European Underwriting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611141887/en/ Nick Selby, Executive Vice President and Head of European Underwriting at Evertas (Photo: Business Wire) Selby, an accomplished information and physical security professional, brings two decades of expertise in public and private sector information security, physical security, and complex incident handling, as well as seven years of experience leading teams securing billions of dollars in cryptoassets. Previously, his roles included VP of the Software Assurance Practice at Trail of Bits, Chief Security Officer at Paxos Trust Company, and Director of Cyber Intelligence and Investigations at the NYPD Intelligence Bureau. “Nick is an extremely valuable addition to our European team,” said Evertas CEO and Co-Founder J. Gdanski. “His public and private
Owlet utvider globalt fotavtrykk med lanseringen av medisinsk-sertifisert Dream Sock™ i Storbritannia og over hele Europa11.6.2024 11:00:00 CEST | Pressemelding
Owlet, Inc. («Owlet» or the «Company») (NYSE:OWLT), pioneren innen smart spedbarnsovervåking, kunngjør i dag den britiske og europeiske lanseringen av Dream Sock. Dette er en smart babymonitor med levende helseavlesninger og varsler for friske spedbarn mellom 0-18 måneder og 2,5-13,6 kg. Dette innovative medisinske utstyret gir foreldre helse og viktig informasjon i sanntid, noe som gir uovertruffen trygghet. Denne pressemeldingen inneholder multimedia. Se hele pressemeldingen her: https://www.businesswire.com/news/home/20240611820341/no/ (Photo: Business Wire) «Vi er svært stolte over å lansere Dream Sock til omsorgspersoner over hele Storbritannia og Europa og gi millioner av foreldre mer trygghet mens babyen sover,» sa Kurt Workman, Owlets administrerende direktør og medgründer. «Dream Sock er nå et globalt produkt som er anerkjent som medisinsk nøyaktig og trygt, etter å ha gjennomgått regulatoriske autorisasjoner og sertifiseringer innenfor flere geografier. I dag er misjonen vår
V-Nova Surpasses 1000 Patent Milestone in Media Technology Innovation11.6.2024 10:00:00 CEST | Press release
V-Nova, a leading provider of data compression solutions, video compression technology, XR technology, AI acceleration and parallel processing for a multitude of industries including media and entertainment, today announced its milestone achievement of 1000 active technology patents. This accomplishment underscores V-Nova’s dedication to research and development and its commitment to protecting its intellectual property globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611724561/en/ V-Nova’s patent portfolio spans more than 50 different jurisdictions. Including over 400 patents in Europe, over 200 in the Americas, over 100 in the United States specifically, and over 200 in Asia. V-Nova forged new directions in data processing to enhance digital experiences, maximize efficiency, reduce costs, and increase sustainability. The company leads the way with key international data compression standards for the video indust
Alipay+ Reveals Top Scorer Trophy Design for UEFA EURO 2024™11.6.2024 09:24:00 CEST | Press release
Alipay+, a suite of cross-border mobile payment and digitalization technology solutions operated by Ant International and an Official Partner of UEFA EURO 2024™, today revealed the trophy that will be awarded to the most prolific marksman at the UEFA EURO 2024™ finale on July 14 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240610328619/en/ The UEFA Top Scorer Trophy presented by Alipay+ is unveiled for UEFA EURO 2024™ (Photo: Business Wire) Sculpted in the shape of the Chinese character “支” (pronounced zhi, and meaning payment as well as support), the trophy reflects Alipay+’s dedication to supporting consumers to enjoy seamless payment and a broad choice of deals using their preferred payment methods while traveling abroad. The character also resembles the fleeting moment of a barefooted striker poised to shoot, evoking the original beauty and power of football – a game that united people across the wo